Decheng Capital Management III as of June 30, 2022
Portfolio Holdings for Decheng Capital Management III
Decheng Capital Management III holds 25 positions in its portfolio as reported in the June 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals (ZNTL) | 19.4 | $51M | 1.8M | 28.10 | |
| Alpine Immune Sciences (ALPN) | 15.2 | $40M | 4.7M | 8.51 | |
| Cue Health (HLTH) | 10.9 | $29M | 9.0M | 3.20 | |
| Illumina (ILMN) | 10.8 | $28M | 154k | 184.36 | |
| Arcus Biosciences Incorporated (RCUS) | 8.4 | $22M | 870k | 25.34 | |
| 10x Genomics Cl A Com (TXG) | 5.2 | $14M | 304k | 45.25 | |
| Albireo Pharma | 3.9 | $10M | 518k | 19.86 | |
| Equillium (EQ) | 3.4 | $9.1M | 4.4M | 2.04 | |
| Adicet Bio (ACET) | 3.2 | $8.5M | 580k | 14.60 | |
| BeyondSpring SHS (BYSI) | 2.7 | $7.1M | 5.0M | 1.44 | |
| Prometheus Biosciences | 2.7 | $7.1M | 250k | 28.23 | |
| Aadi Bioscience (AADI) | 2.5 | $6.5M | 526k | 12.32 | |
| Pacific Biosciences of California (PACB) | 2.5 | $6.5M | 1.5M | 4.42 | |
| Horizon Therapeutics | 1.7 | $4.4M | 55k | 79.77 | |
| Sema4 Holings Corp. Com Cl A | 1.6 | $4.3M | 3.4M | 1.26 | |
| Mersana Therapeutics (MRSN) | 1.6 | $4.2M | 904k | 4.62 | |
| Aura Biosciences (AURA) | 1.1 | $3.0M | 210k | 14.17 | |
| AtriCure | 0.7 | $1.9M | 46k | 40.86 | |
| Terns Pharmaceuticals (TERN) | 0.7 | $1.8M | 714k | 2.48 | |
| Owlet Com Cl A | 0.6 | $1.5M | 898k | 1.70 | |
| Neubase Therapeutics Ord | 0.4 | $1.1M | 1.0M | 1.05 | |
| Scynexis Com New (SCYX) | 0.4 | $1.0M | 556k | 1.86 | |
| Nautilus Biotechnology (NAUT) | 0.3 | $807k | 300k | 2.69 | |
| 908 Devices (MASS) | 0.2 | $412k | 20k | 20.60 | |
| Singular Genomics Systems In (OMIC) | 0.0 | $76k | 20k | 3.80 |
